Ozanimod shows efficacy in two-year study extension
Ozanimod shows efficacy in two-year study extension
Results from the extension period of a Phase II trial, assessing Ozanimod as a potential treatment for relapsing-remitting multiple sclerosis, showed that the drug can effectively and safely improve clinical measures of RRMS after two years of treatment...Read more - http://www.ms-uk.org/ozanimod-shows-eff ... ion-260916
MS-UK - http://www.ms-uk.org/